Ultragenyx is a rare-disease commercial platform priced like a cash-burning biotech—its next re-rating depends on 2026–2027 gene-therapy execution and a potentially scale-changing Angelman Phase 3 readout.
Ultragenyx Pharmaceutical Inc. (RARE) is a commercial-stage biopharmaceutical organization dedicated to the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases.[1, 2] The company operates at the intersection of high-science drug discovery and specialized commercial execution, focusing on conditions with high unmet medical needs where the underlying biology is clearly defined.[3, 4] As of early 2026, the company has transitioned from a pure-play research entity into a multi-product commercial enterprise with four approved therapies: Crysvita, Dojolvi, Mepsevii, and Evkeeza.[2, 5]
The revenue generation model is diversified across direct product sales, primarily in Latin America and Türkiye, and significant royalty streams from the United States, Canada, and Europe.[6] In fiscal year 2025, Ultragenyx reported total revenue of $673 million, representing a robust 20% year-over-year growth.[6] The economic centerpiece of the portfolio is Crysvita, a monoclonal antibody for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), which accounted for $481 million of the 2025 total.[6] This is supplemented by Dojolvi, a synthetic triglyceride for long-chain fatty acid oxidation disorders (LC-FAOD), which contributed $96 million in 2025.[6]
The company’s core products target metabolic, bone, and neurogenetic disorders.[2, 7] Crysvita functions by neutralizing excess fibroblast growth factor 23 (FGF23), while Dojolvi provides an alternative energy source for patients who cannot metabolize long-chain fats.[5, 8] Primary customers include specialized metabolic centers, pediatric hospitals, and government healthcare systems globally.[8, 9] Customers choose Ultragenyx therapies primarily because they are often the first or only disease-modifying treatments approved to address the root cause of these devastating conditions.[3, 4]
Strategically, Ultragenyx is currently executing a pivotal shift toward financial sustainability.[6] In response to a 2025 net loss of $575 million and the failure of its setrusumab program in December 2025, management has initiated a restructuring plan aimed at a 15% reduction in operating expenses by 2027.[6, 10, 11] This plan is designed to pave a path toward full-year GAAP profitability in 2027, supported by a late-stage pipeline that includes two potential gene therapy approvals in 2026 and a transformative Phase 3 readout for Angelman syndrome.[5, 6, 12]
Rare Disease Leader
The commercial success of Ultragenyx is anchored in its ability to navigate the complex regulatory and reimbursement landscapes of orphan diseases. The company’s revenue is not merely a function of sales volume but is deeply tied to the clinical necessity of its offerings and the durability of its patient base.[8]
Crysvita (burosumab): The Foundation of Growth
Crysvita is a recombinant fully human IgG1 monoclonal antibody that binds to and inhibits the biological activity of FGF23.[5] In patients with XLH, a genetic form of rickets, overproduction of FGF23 leads to renal phosphate wasting and a deficiency in active vitamin D, resulting in severe bone mineralization defects, pain, and physical impairment.[8]
* Revenue Dynamics: The product is commercialized through a collaboration with Kyowa Kirin (KKC). Ultragenyx records product sales in Latin America and Türkiye ($177 million in 2025) and earns royalties on sales in the U.S., Canada, and Europe ($304 million in 2025).[6] The 17% growth in Crysvita revenue in 2025 underscores its continued penetration into adult and pediatric populations globally.[6, 13]
* Monetization Strategy: Ultragenyx has utilized the steady cash flows from Crysvita to fund its high-risk R&D. In November 2025, the company secured $400 million by selling an additional 25% of its U.S. and Canadian royalty interest to OMERS, demonstrating the high market value of this long-term asset.[5, 14]
Dojolvi (triheptanoin): A Unique Metabolic Small Molecule
Dojolvi is a highly purified, synthetic, seven-carbon (C7) fatty acid triglyceride.[15, 16] It is the first and only FDA-approved therapy for molecularly confirmed LC-FAOD.[16] In these patients, the body cannot convert long-chain fats into energy, leading to life-threatening metabolic crises, rhabdomyolysis, and cardiomyopathy.[15, 17]
* Mechanism of Action: Triheptanoin provides anaplerotic metabolites (three-carbon and four-carbon fragments) that enter the Citric Acid (TCA) cycle directly, effectively bypassing the blocked long-chain oxidation pathway and restoring cellular energy balance.[18]
* Economic Impact: Generating $96 million in 2025, Dojolvi represents a high-margin small molecule opportunity.[6] While it faces geographic reimbursement scrutiny (as seen in Canada), its unique clinical profile provides significant pricing power.[18]
Evkeeza (evinacumab) & Mepsevii (vestronidase alfa): Specialized Growth
Evkeeza is an ANGPTL3 inhibitor for patients with homozygous familial hypercholesterolemia (HoFH), where it provides significant LDL-C reduction regardless of LDL receptor function.[5] Ultragenyx manages its launch in territories outside the U.S., contributing $59 million in 2025, a massive 84% increase from 2024.[6] Mepsevii, an ERT for MPS VII, provides a stable $37 million revenue base for the company's lysosomal storage disease franchise.[6]
Ultragenyx has constructed a multi-layered moat that is difficult for traditional biotechnology firms to replicate, particularly in the gene therapy space.
The addressable market for Ultragenyx is currently expanding from ultra-rare metabolic niches toward larger neurogenetic and bone populations.
| Product / Program | Indication | Estimated Target Population (Accessible) | Market Potential Context |
|---|---|---|---|
| Crysvita | XLH / TIO | 1 in 20,000 prevalence [8] | Established global standard of care. |
| Dojolvi | LC-FAOD | 5,000 patients [8, 16] | High unmet need; only approved therapy. |
| GTX-102 | Angelman Syndrome | 60,000 patients [23, 24] | Significant multi-billion dollar neurogenetic opportunity. |
| DTX401 | GSDIa | 6,000 patients [3] | First potential gene therapy for the condition. |
| DTX301 | OTC Deficiency | 10,000 patients [4, 25] | Targets the most common urea cycle disorder. |
| UX111 | MPS IIIA | 3,000 - 5,000 patients [12, 21] | Fatal childhood disease with no approved treatment. |
The most important strategic shift is the movement into Angelman Syndrome (GTX-102). With 60,000 patients, this single program has the potential to triple the company's current commercial scale.[24] Furthermore, the gene therapy pipeline (GSDIa and OTC) targets "functional cures" that, while one-time treatments, carry premium pricing potential typically ranging from $2M to $3.5M per patient based on peer benchmarks.[26]
Ultragenyx is a leader in the mid-sized biotech tier, competing with both larger diversified pharmaceutical companies and nimble, platform-specific startups.
Clinical & Manufacturing Moat
Fiscal year 2025 was a year of "growth amidst restructuring" for Ultragenyx. The company exceeded the top end of its revenue guidance while simultaneously initiating significant cost-cutting measures.[1, 6, 10]
| Financial Metric (USD Millions) | FY 2025 (Preliminary/Actual) | FY 2024 (Actual) | Year-over-Year Change (%) |
|---|---|---|---|
| Total Revenue | $673.0 [6] | $560.0 [6] | +20% |
| Crysvita Revenue | $481.0 [6] | $410.0 [6] | +17% |
| Dojolvi Revenue | $96.0 [6] | $88.0 [6] | +9% |
| Evkeeza Revenue | $59.0 [6] | $32.0 [6] | +84% |
| Cost of Sales | $105.0 (Est.) | $79.7 (9mo) [5] | ~30% |
| R&D Expense | $712.0 (Est.) | $546.7 (9mo) [5] | Flat to Slight Increase |
| SG&A Expense | $348.0 (Est.) | $261.1 (9mo) [5] | +8% |
| Net Loss | ($575.0) [11] | ($583.0) (Est.) | Improved |
| Cash & Marketable Securities | $737.0 [10] | $610.0 (Dec 24) [33] | +21% |
The primary driver of 2025's revenue outperformance was the successful expansion of the international commercial team, particularly in Latin America, and the rapid uptake of Evkeeza outside the U.S..[5, 6] However, the net loss remains high at $575 million, which the company aims to address through its strategic restructuring plan announced in early 2026.[6, 10, 11]
Ultragenyx is valued by the market primarily as a "bridge to profitability" story. The traditional P/E ratio is irrelevant given current losses, but the Price-to-Sales (P/S) and Enterprise Value-to-Revenue (EV/Rev) multiples provide a framework for comparison.
The intrinsic value of Ultragenyx is concentrated in its commercial infrastructure and its proprietary manufacturing facility. Unlike virtual biotech companies, Ultragenyx owns its distribution channels and its science. This "full-stack" model justifies a higher terminal multiple (5.0x Sales) than a pure-play R&D shop.[2, 3] The bridge to valuation is not just multiple expansion but the conversion of "spent R&D" into "commercial cash flow" starting in 2027.[6, 10]
Transition to Profitability
The most immediate risk to the Ultragenyx thesis is the management of its late-stage gene therapy submissions.
* CMC and Regulatory Hurdles: The February 2026 Incomplete Response Letter (IRL) for UX111 highlights the difficulty of AAV gene therapy manufacturing.[21] If the company cannot provide the "additional supportive documentation" required by the FDA, the launch of UX111 could be delayed by 12-18 months, leading to a significant revenue gap and potentially necessitating a dilutive capital raise.[21, 37]
* Clinical Data Failure: The December 2025 Phase 3 failure of setrusumab (UX143) serves as an "early warning sign" of the inherent volatility in bone disease research.[2, 31, 32] A similar failure in the GTX-102 Aspire study would be catastrophic, as Angelman syndrome is the primary driver of the long-term bull case.[24, 32]
High Execution Risk
The following scenarios utilize a 2030 horizon, assuming a starting price of $22.87 [34] and current shares outstanding of ~97 million.[21]
In the base case, Ultragenyx achieves approvals for DTX401 and UX111 by late 2026 or early 2027.[3, 12] The restructuring plan is successful, and the company reaches GAAP profitability by Q4 2027.[6, 10] GTX-102 data is positive, leading to a 2028 launch in Angelman syndrome.[24]
* Revenue 2030: $2.05 Billion (25% CAGR from 2025).[36]
* Margin Assumption: 15% Net Margin (driven by R&D expense reduction and high-margin gene therapy sales).[10]
* Exit Multiple: 5.0x EV/Revenue.
* Valuation: $10.25B Target EV.
* Projected Share Price: $94.00.
In the high case, GTX-102 becomes a global blockbuster, treating a large portion of the 60,000 Angelman patients.[24] Crysvita adult penetration exceeds expectations, and Evkeeza becomes a multi-hundred million dollar franchise international.[6] The company becomes a prime M&A target for a large pharmaceutical player (e.g., Kyowa Kirin or Amgen).[39]
* Revenue 2030: $3.5 Billion (39% CAGR).
* Margin Assumption: 25% Net Margin (economies of scale in manufacturing).
* Exit Multiple: 7.0x EV/Revenue (reflecting M&A premium).
* Valuation: $24.5B Target EV.
* Projected Share Price: $225.00.
In the low case, the UX111 IRL is not resolved quickly, and DTX401 faces a safety signal.[21] GTX-102 data in Angelman syndrome is ambiguous, allowing Roche to lead the market.[27] The company fails to reach profitability in 2027, burning through its $737M cash reserve and forcing multiple dilutive equity rounds.[10, 37]
* Revenue 2030: $950 Million (Crysvita and Dojolvi mature, but no new blockbuster launches).
* Margin Assumption: Continued Net Losses (Negative -5%).
* Exit Multiple: 1.5x EV/Revenue.
* Valuation: $1.4B Target EV.
* Projected Share Price: $11.00.
| Year | Projected Revenue ($M) | Projected Net Income ($M) | Projected Share Count (M) | Implied Price Target |
|---|---|---|---|---|
| 2025A | $673 [6] | ($575) [11] | 97 [21] | $22.87 [34] |
| 2026E | $745 [10] | ($450) | 100 | $35.00 |
| 2027E | $950 | $20 | 104 | $52.00 |
| 2028E | $1,300 | $150 | 107 | $68.00 |
| 2029E | $1,750 | $300 | 110 | $82.00 |
| 2030E | $2,050 | $400 | 113 | $94.00 |
| Scenario | Year 5 Revenue | Margin / Earnings Assumption | Valuation Multiple (EV/S) | Implied Future Price | 5-Year Total Return | Probability |
|---|---|---|---|---|---|---|
| High Case | $3,500M | 25% Net Margin | 7.0x | $225.00 | ~883% | 25% |
| Base Case | $2,050M | 15% Net Margin | 5.0x | $94.00 | ~310% | 55% |
| Low Case | $950M | -5% Net Margin | 1.5x | $11.00 | -52% | 20% |
Probability Weighted Price Target: $109.90
Asymmetric Upside Potential
Founder and CEO Emil Kakkis is a rare-disease pioneer with significant personal reputational and financial skin in the game. Compensation is heavily weighted toward performance-based equity (PSUs), and stock ownership guidelines (3x salary for the CEO) ensure long-term focus.[40] While CFO Howard Horn has engaged in routine 10b5-1 selling, his remaining stake of ~80,000 shares is substantial.[38, 40]
Revenue is high-quality, consisting of global pharmaceutical sales for chronic, life-saving conditions.[8] The mix of direct sales and passive royalties from world-class partners like Kyowa Kirin and Regeneron provides a stable base.[5] The durability of the Crysvita franchise is a significant asset.[6]
Ultragenyx is the undisputed leader in its current commercial segments (XLH, LC-FAOD) and is positioned to be a first-mover in GSDIa and Angelman syndrome.[3, 8, 24] Its integrated manufacturing facility is a major competitive advantage in the gene therapy space.[3]
The company possesses one of the densest late-stage pipelines in the biotechnology sector. With multiple Phase 3 programs (Angelman, OTC, Wilson disease) and potential approvals in 2026, the growth runway is exceptional.[9, 10, 14]
This is the company’s primary weakness. Sustained losses and high cash burn ($466M in 2025) have necessitated royalty monetization and equity issuance.[10, 11] However, the $737M cash position and path to 2027 profitability provide a viable bridge.[6, 10]
The business is highly durable due to the "stickiness" of the rare disease patient population and the biological necessity of the treatments.[8] Choke points are largely regulatory and manufacturing-related rather than demand-driven.[3, 12]
Management has been creative in securing non-dilutive funding via the OMERS royalty deals.[5] However, the failure of the setrusumab program and high operating expenses prior to 2026 reflect a "spend-heavy" historical approach that is only now being corrected.[10, 31]
Wall Street remains bullish, with 89% of analysts maintaining "Buy" or "Strong Buy" ratings.[36, 41] The average price target of ~$60 indicates significant perceived undervaluation from current levels.[42, 43]
Currently non-existent on a GAAP basis.[11] The score reflects historical performance, but the forward-looking trajectory is positive as the company pivots toward its 2027 goal.[6]
The company has successfully brought four drugs to market—a rare feat in biotech.[5] However, recent clinical failures and the UX111 BLA setback have tarnished the track record in the eyes of short-term investors.[21, 31]
Overall Blended Score: 7.4 / 10
High-Growth Strategic Play
The investment thesis for Ultragenyx Pharmaceutical is centered on the transition from a high-burn research organization to a profitable, multi-product commercial leader. In 2025, the company demonstrated its commercial prowess by growing revenue 20% and surpassing the $670 million threshold, driven by the durability of the Crysvita franchise and the rapid international expansion of Evkeeza.[1, 6]
Key catalysts for the next 12-24 months include the potential FDA approval of DTX401 for GSDIa (PDUFA August 23, 2026) and the resubmission of the UX111 BLA following the February 2026 CMC-related Incomplete Response Letter.[3, 12, 21] Most critically, the second half of 2026 will bring pivotal Phase 3 data for GTX-102 in Angelman syndrome, a program with multi-billion dollar revenue potential that could redefine the company’s scale.[24, 44]
While risks related to cash burn, regulatory 제조(manufacturing) hurdles, and the competitive landscape for gene therapy remain, the company’s current valuation (3.3x sales) appears to discount much of the pipeline’s potential value.[31, 35] The management's restructuring plan to reduce expenses by 15% and achieve profitability by 2027 is the essential bridge that will allow investors to realize the value of the underlying rare-disease assets.[6, 10] For investors seeking exposure to the next generation of genetic medicine, Ultragenyx represents a de-risked commercial platform with significant clinical optionality.
Pivotal Growth Inflection
Ultragenyx (RARE) is currently trading in a consolidation phase following the December 2025 setrusumab failure.[31] At ~$22.87, the stock is trading just above its 50-day moving average ($22.25) but remains significantly below its 200-day moving average of $27.85.[38] Recent news of the UX111 BLA acceptance in April 2026 triggered a 4.8% upward move, signaling that the market is beginning to price in a recovery.[37, 38] The short-term outlook is neutral-to-positive, with the stock likely to remain in a range between $20 and $28 until the next major regulatory update for DTX401 or UX111.[10, 34]
Basing for Breakout
View Ultragenyx Pharmaceutical Inc. (RARE) stock page
Loading the interactive version of this report…